Share on StockTwits

Acceleron Pharma (NASDAQ:XLRN) SVP Matthew L. Sherman sold 2,500 shares of Acceleron Pharma stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $29.62, for a total transaction of $74,050.00. Following the completion of the transaction, the senior vice president now directly owns 27,858 shares in the company, valued at approximately $825,154. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

XLRN has been the subject of a number of recent research reports. Analysts at Leerink Swann initiated coverage on shares of Acceleron Pharma in a research note on Thursday, August 14th. They set an “outperform” rating and a $57.00 price target on the stock. Analysts at FBR Capital Markets initiated coverage on shares of Acceleron Pharma in a research note on Wednesday, August 13th. They set an “outperform” rating and a $47.00 price target on the stock. Four investment analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average price target of $51.00.

Acceleron Pharma (NASDAQ:XLRN) traded down 2.92% on Tuesday, hitting $28.62. 75,625 shares of the company’s stock traded hands. Acceleron Pharma has a 52 week low of $16.78 and a 52 week high of $57.89. The stock’s 50-day moving average is $29.49 and its 200-day moving average is $35.64. The company’s market cap is $910.0 million.

Acceleron Pharma (NASDAQ:XLRN) last announced its earnings results on Tuesday, August 12th. The company reported ($0.54) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.55) by $0.01. On average, analysts predict that Acceleron Pharma will post $-1.44 earnings per share for the current fiscal year.

Acceleron Pharma Inc is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases.

Receive News & Ratings for Acceleron Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acceleron Pharma Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.